ONCOSeq™ Panel
The RainDance ONCOSeq™ Research Screening Panel enables researchers to simultaneously sequence 142 cancer genes, including more than 90% of the genes represented in the Sanger Institute’s Cancer Gene Census, all in a single assay. With the ONCOSeq panel, researchers can now cost-effectively apply next-generation sequencing technology more routinely to detect known and novel mutations across a complete panel of cancer related genes.
Comprehensive Content
The RainDance ONCOSeq Research Screening Panel utilizes next-generation sequencing technology to offer greater than 99% coverage of 142 oncogenes. Target all of the coding exons including the intron-exon junctions to detect splice site mutations as well as 1,000 bases from the 5’ promoter region and 3’ UTR for each gene. Detect many different mutation types including missense and nonsense mutations, amplifications, frameshifts, splice site mutations, and deletions.
ONCOSeq Panel Advantages
- Sequence more relevant oncogenes at the same time: Analyze all of the exons from 142 cancer genes including intron-exon junctions and 1,000 bases from the 5′ and 3′ regulatory regions.
- Eliminate enrichment bias: Maintain allelic representation of heterozygous alleles with single molecule PCR. Eliminates under-representation of mutant alleles.
- Take advantage of low starting input requirements: Requires as little as 250 ng of genomic DNA.
- Simplify workflow: Target regions of interest with more than 2 million PCR products per sample in less than 1 hour and decrease overall processing time to less than 8 hours compared to multiday hybridization-based sequence enrichment methods.
- Discover low frequency somatic alleles: Detect alleles at a frequency as low as 5% of a heterogeneous sample.
- Customize additional content: Add more genes for user-specific needs.
*The RainDance ONCOSeq™ Screening Panel is for Research Use Only. Not for use in diagnostic procedures.